NKB61 / PersonGen Biomedicine - LARVOL DELTA

NKB61: A Novel PD-1 Agonist/CD16A Bispecific Antibody with Selective Depletion of Pathogenic PD-1+ T Cells and Favorable Safety Profile for Autoimmune Disease Therapy (ACR Convergence 2026) - "NKB61 is a first-in-class bispecific antibody that combines PD-1 agonism with enhanced ADCC to selectively deplete pathogenic PD-1+ T cells while sparing Tregs. Its excellent safety profile and potent in vivo efficacy in non-human primates support rapid advancement to Phase I clinical trials, with a priority focus on autoimmunities driven by pathogenic T cells, such as RA and IBD. Figure 1."

Bispecific • Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Rheumatoid Arthritis • Systemic Lupus Erythematosus • CD4 • CD8 • CRP • FCGR3A • FOXP3 • IFNG • IL2 • IL2RA • IL6 • TNFA